Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
NCT ID: NCT04608305
Last Updated: 2023-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
843 participants
INTERVENTIONAL
2020-10-28
2022-10-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, a vaccine developed by IIBR for SARS-CoV-2 virus will be assessed for its safety and potential efficacy in volunteers. The study is comprised of two phases, a dose-escalation phase (phase I) during which subjects (18-55 years old) will be randomly allocated to receive a single administration of IIBR-100 at low, mid or high dose or saline or two administrations of IIBR-100 at low dose, or saline, 28 days apart.
Based on results obtained during phase I, and cumulative phase I data review, the expansion phase (phase II) has begun, during which larger cohorts as well as elderly age subjects were initially planned to be randomly allocated to receive a single administration of IIBR-100 at low, mid or high dose or saline, or two administrations of IIBR-100 at low, mid or high dose (prime-boost) or saline, 28 days apart. Additional top-dose (prime-boost) may be implemented when immunogenicity of any prime-boost arm is considered insufficient. However, based on immunogenicity preliminary data and DSMB recommendations, only the two administrations of mid, high and top dose (prime-boost) or saline will continue in the study.
The subjects will be followed for a period of up to 12 months post last vaccine administration to assess the safety and efficacy of the vaccine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Reactogenicity and Immunogenicity Study of ReCOV
NCT04818801
Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)
NCT05113849
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
NCT05903118
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
NCT04352608
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
NCT04412538
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
Dosing of prime during phase I occurred in a sequential fashion (partially overlapping), starting from low-dose and continuing to mid and high doses following safety reviews. Prior to expansion to phase II, cumulative data from phase I was evaluated (dose and regimen) by the data safety monitoring board. The DSMB's recommendations regarding expansion to phase II were the continuation of prime-boost regimens of medium, high and top doses.
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
phase I - Group Ia, prime, low dose
Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E5 pfu/ml or saline placebo at day 0
IIBR-100, low dose (prime)
Single administration of IIBR-100 1\*10E5 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
phase I - Group Ib, Prime, medium dose
Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E6 pfu/ml or saline placebo at day 0
IIBR-100 medium dose (prime)
Single administration of IIBR-100 1\*10E6 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
phase I - Group Ic, Prime, high dose
Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E7 pfu/ml or saline placebo at day 0
IIBR-100 high-dose (prime)
Single administration of IIBR-100 1\*10E7 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
phase I - Group Id, prime-boost, low dose
Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
IIBR-100 low-dose (prime-boost)
Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
phase II - Group IIa, prime, low dose*
Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E5 pfu/ml or saline placebo at day 0.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100, low dose (prime)
Single administration of IIBR-100 1\*10E5 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
Phase II - Group IIb, Prime, low dose, elderly subjects*
Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1\*10E5 pfu/ml or saline placebo at day 0.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100, low dose (prime)
Single administration of IIBR-100 1\*10E5 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
phase II - Group IIc, Prime, medium dose*
Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E6 pfu/ml or saline placebo at day 0.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100 medium dose (prime)
Single administration of IIBR-100 1\*10E6 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
phase II - Group IId, Prime, medium dose, elderly subjects*
Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1\*10E6 pfu/ml or saline placebo at day 0.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100 medium dose (prime)
Single administration of IIBR-100 1\*10E6 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
Phase II - Group IIe, prime, high dose*
Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E7 pfu/ml or saline placebo at day 0.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100 high-dose (prime)
Single administration of IIBR-100 1\*10E7 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
Phase II - Group IIf, Prime, high dose, elderly subjects*
Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1\*10E7 pfu/ml or saline placebo at day 0.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100 high-dose (prime)
Single administration of IIBR-100 1\*10E7 pfu/ml
Saline Placebo (single)
Single administration of saline placebo
phase II - Group IIg, prime-boost, low dose*
Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E5 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100 low-dose (prime-boost)
Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
phase II - Group IIh, prime-boost, low dose, elderly subjects*
Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations.
IIBR-100 low-dose (prime-boost)
Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
phase II - Group IIi, prime-boost, medium dose
Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E6 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 medium-dose (prime-boost)
Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
phase II - Group IIj, prime-boost, medium dose, elderly subjects
Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E6 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 medium-dose (prime-boost)
Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
phase II - Group IIk, prime-boost, high dose
Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E7 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 high-dose (prime-boost)
Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
phase II - Group IIl, prime-boost, high dose, elderly subjects
Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E7 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 high-dose (prime-boost)
Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
phase II - Group IIm, prime-boost, top dose
Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E8 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 top-dose (prime-boost)
Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
phase II - Group IIn, prime-boost, top dose, elderly subjects
Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E8 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 top-dose (prime-boost)
Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IIBR-100, low dose (prime)
Single administration of IIBR-100 1\*10E5 pfu/ml
IIBR-100 medium dose (prime)
Single administration of IIBR-100 1\*10E6 pfu/ml
IIBR-100 high-dose (prime)
Single administration of IIBR-100 1\*10E7 pfu/ml
IIBR-100 low-dose (prime-boost)
Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
Saline Placebo (single)
Single administration of saline placebo
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 medium-dose (prime-boost)
Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
IIBR-100 high-dose (prime-boost)
Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
IIBR-100 top-dose (prime-boost)
Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy males or females, ages 18 to 55 (inclusive) at the time of screening.
* Negative PCR and no presence of ELISA antibody titers to SARS-CoV-2 at screening.
* Females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (OCP, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (IUD) or intrauterine system (IUS) from at least 14 days prior to vaccination through 90 days following last injection.
* Subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination.
* No clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening.
* Negative HIV, Hepatitis B and Hepatitis C serology tests.
* Normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmHg)
* Must be willing to forgo blood donation during the blood drawing phase of the study.
* Must agree not to enroll in another study of an investigational agent prior to completion of the study.
* Subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions.
* Ability to provide informed consent.
Phase II (abbreviated):
* Males or females, ages 18 to 85 (inclusive) at the time of screening.
* Negative PCR and no presence of ELISA antibody titers to SARS-CoV-2 at screening.
* Females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (OCP, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (IUD) or intrauterine system (IUS) from at least 14 days prior to vaccination through 90 days following last injection. Male must agree to avoid sperm donation from time of first injection through 90 days following last injection.
* No clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening.
* Must be willing to forgo blood donation during the blood drawing phase of the study
* Must agree not to enroll in another study of an investigational agent prior to completion of the study.
* Normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmHg).
* Subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions.
* Ability to provide informed consent.
Exclusion Criteria
* History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions or known allergy to the components of the vaccine, including allergy to rice.
* Receipt of investigational product up to 30 days prior to screening or ongoing participation in another clinical trial
* Receipt of licensed vaccines within 14 days of planned study immunization and any AE's possibly related to licensed vaccine immunization at Day 0.
* Inability to observe possible local reactions at the injection sites due to a physical condition or permanent body art.
* Known hemoglobinopathy or coagulation abnormality.
* New onset of fever \>37.8 ºC AND \[cough OR shortness of breath OR anosmia/ageusia\] or any other inter current illness within 14 days prior to screening
* High risk of exposure to SARS-CoV-2 prior to enrollment (close contact, self-isolation at present due to household contact, frontline healthcare provider in contact with COVID-19 subjects).
* Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health, per the best clinical judgement of the investigator.
* Women who are pregnant or breastfeeding.
* Positive urine pregnancy test or women have an intention to be pregnant during the study.
* Confirmed or suspected illness caused by coronaviruses, SARS-CoV 1, and Middle East Respiratory Syndrome (MERS)-CoV.
* Received any prior vaccine against a coronavirus
* Receipt of blood/plasma products or immunoglobulin, from within 60 days before study intervention administration or planned receipt throughout the study.
* History of alcohol or drug abuse per clinical judgement within 5 years prior to study vaccination.
* Participants who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
* Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study.
* Individuals who are living with severely immunocompromised people (e.g. transplant patients, those under active cancer immunosuppressant therapy), pregnant women, lactating women, children under 12 months old, or any other individual that, in the judgment of the investigator, might be at increased risk.
Phase II (abbreviated):
* History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions or known allergy to the components of the vaccine, including allergy to rice.
* Receipt of investigational product (except of confirmed placebo in IIBR20-001 study) up to 30 days prior to screening or ongoing participation in another clinical trial (except of IIBR20-001 trial).
* Receipt of licensed vaccines within 14 days of planned study immunization and any AE's possibly related to licensed vaccine immunization at Day 0.
* Inability to observe possible local reactions at the injection sites due to a physical condition or permanent body art.
* Known hemoglobinopathy or coagulation abnormality (subjects treated by anticoagulation or anti platelets are not excluded).
* New onset of fever \>37.8ºC AND \[cough OR shortness of breath OR anosmia/ageusia\], or any other inter current illness within 14 days prior to screening
* Factors that increase risk to the subject to severe disease per CDC guidance including the following risk factors (in any case of ambiguous grading, decision will be made per investigator's best clinical judgement): Cancer \[ongoing malignancy or recently diagnosed malignancy in the last five years, not including non-melanotic skin cancer\], Chronic Kidney Disease (eGFR\<60 mL/min/1.73 m\^2), liver disease (ALT or AST) \> 1.5 × ULN; or alkaline phosphatase and direct bilirubin \> ULN (total bilirubin may be up to 2 × ULN as long as direct bilirubin is equal to or below the ULN); or PT INR \> 1.25), COPD; Immunocompromised state from solid organ transplant; Obesity (BMI≥30kg/m2); Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies; Sickle cell disease; Type 1/2 diabetes mellitus (HbA1C\>8.0%, per medical history questioning or records) ); Asthma; Cerebrovascular disease; Cystic fibrosis, uncontrolled hypertension that does not respond to therapy, Pulmonary fibrosis, Thalassemia.
* Anticipating the need for immunosuppressive treatment within the next 6 months.
* Clinically significant (by means of potentially risking the subject or that would be potentially detrimental to the results of the study) medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health or for severe COVID-19, per the investigator.
* Any progressive or severe neurologic condition/disorder, dementia, seizure disorder, or history of Guillian-Barré syndrome.
* Known or suspected impairment of the immune system including rheumatic, connective tissue or vascular disease of autoimmune origin
* Women who are pregnant or breastfeeding.
* Positive urine or serum pregnancy test or women have an intention to be pregnant during the study.
* Clinically significant abnormal CBC results in WBC, hemoglobin, hematocrit, or platelets.
* Clinically significant abnormal urinalysis: RBC, protein, or glucose only.
* Positive serology for: hepatitis B surface antigen, hepatitis C, HIV.
* Known or suspected illness caused by coronaviruses, SARS-CoV 1, and Middle East Respiratory Syndrome (MERS)-CoV..
* Received any prior vaccine against a coronavirus.
* Receipt of blood/plasma products or immunoglobulin, from within 60 days before study intervention administration or planned receipt throughout the study.
* Immunosuppressive medications received within 90 days before screening. (Not including \[1\] corticosteroid nasal spray for allergic rhinitis; \[2\] topical corticosteroids for mild, uncomplicated dermatitis; or \[3\] oral/parenteral corticosteroids given for non-chronic conditions not expected to recur \[length of therapy 10 days or less with completion at least 30 days prior to vaccination\].)
* History of alcohol or drug abuse per clinical judgement within 5 years prior to study vaccination (excluding cannabis)
* Participants who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
* Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study.
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Israel Institute for Biological Research (IIBR)
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assuta - University Hospital
Ashdod, , Israel
Barzilai MC
Ashkelon, , Israel
Rambam MC
Haifa, , Israel
Hadassah Medical Center
Jerusalem, , Israel
Meir MC
Kfar Saba, , Israel
Rabin MC
Petah Tikva, , Israel
Sheba Medical Center Hospital- Tel Hashomer
Ramat Gan, , Israel
Sourasky MC
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Caraco Y, Madar-Balakirski N, Ben-Ami E, Zeltser D, Maayan S, Eliakim-Raz N, Peer A, Brosh-Nissimov T, Vishlitzky V, Beth-Din A, Bar-Haim E, Israely T, Paran N, Fisher M, Hoggeg M, Atsmon J, Cohen D, Goldstaub D, Levin Y, Danon Y, Panet A, Shapira S, Yitzhaki S, Marcus H. Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 vaccine development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults. Vaccine. 2025 Oct 16;67:127837. doi: 10.1016/j.vaccine.2025.127837. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIBR 20-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.